Targeting annexin A2 enhances anti-PD-1 immunotherapy in pancreatic ductal adenocarcinoma by remodeling the tumor immune microenvironment
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115504 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Mengmeng Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Zhongshan Hospital of Fudan University, Qingpu Branch, Shanghai, PR China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Annexin A2, Pancreatic Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Science and Technology Commission of Fengxian District, Shanghai Municipality, Fudan University.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis, underscoring the need for novel therapeutic approaches. In this study, we investigate the role of Annexin A2 (ANXA2) in PDAC progression and its potential as a therapeutic target. Single-cell RNA sequencing of PDAC tissues identified distinct subpopulations of ductal cells, with elevated ANXA2 expression strongly correlating with poor patient prognosis. Functional assays, including co-culture systems, flow cytometry, and Western blotting, revealed that ANXA2 regulates the tumor immune microenvironment and supports cancer cell proliferation. In a murine PDAC model, we explored the therapeutic effects of ANXA2 knockdown combined with immune checkpoint blockade (ICB) therapy. Our results showed that ANXA2 inhibition enhanced the efficacy of anti-PD-1 therapy, significantly reducing tumor growth, increasing CD8+ T cell infiltration, and reshaping the immune landscape within the tumor. These findings highlight ANXA2 as a key modulator of PDAC progression and immune evasion. Targeting ANXA2 may optimize existing immunotherapeutic strategies, offering a promising avenue for improving clinical outcomes in PDAC patients. This study provides compelling evidence for the development of ANXA2-targeted therapies in pancreatic cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Affiliated Zhongshan Hospital of Fudan University, Qingpu Branch, Shanghai, PR China.
- Department of Liver Surgery and Transplantation and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, PR China.
- Department of Respiratory and Critical Care Medicine, Shanghai Pudong Hospital, 2800 Gongwei Rd, Shanghai 201399, PR China.
- Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
- CAS Key Laboratory of Nutrition, University of Chinese Academy of Sciences, Shanghai 200000, PR China.
- Department of General Surgery, Affiliated Zhongshan Hospital of Fudan University, Qingpu Branch, Shanghai, PR China. Electronic address: songchao1708@163.com.
Förderung
- Science and Technology Commission of Fengxian District, Shanghai Municipality
- Fudan University
Zitieren
APA
Liu, M., Wang, G., Gao, J., Peng, M., Feng, H., Liang, X., Ding, K., Chen, Y., & Song, C. (2025). Targeting annexin A2 enhances anti-PD-1 immunotherapy in pancreatic ductal adenocarcinoma by remodeling the tumor immune microenvironment. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115504
Vancouver
Liu M, Wang G, Gao J, Peng M, Feng H, Liang X, et al. Targeting annexin A2 enhances anti-PD-1 immunotherapy in pancreatic ductal adenocarcinoma by remodeling the tumor immune microenvironment. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115504
BibTeX
@article{Liu2025,
author = {Liu, Mengmeng and Wang, Ganggang and Gao, Jiameng and Peng, Maozhen and Feng, Haokang and Liang, Xin and Ding, Kai and Chen, Yu and Song, Chao},
title = {Targeting annexin A2 enhances anti-PD-1 immunotherapy in pancreatic ductal adenocarcinoma by remodeling the tumor immune microenvironment},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115504}
}
EUVIMED